FDA Approves Two Vonoprazan Therapies for H pylori Eradication

Vonoprazan-based dual and triple regimens showed superior eradication rates compared with PPI-based triple therapy in a pivotal trial.
FDA Approvals
Vonoprazan-based dual and triple regimens showed superior eradication rates compared with PPI-based triple therapy in a pivotal trial.
FDA Approvals